iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know

iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy) due to a 36.7% increase in the Zacks Consensus Estimate over the past three months, reflecting upward revisions in earnings estimates; the company is expected to earn -$2.68 per share for the fiscal year ending December 2025, a 19.3% change from the prior year. The Zacks Rank upgrade, which places iTeos in the top 20% of Zacks-covered stocks, suggests potential near-term price appreciation driven by institutional investors reacting to the improved earnings outlook.

Analysis

iTeos Therapeutics, Inc. (ITOS) has been upgraded to a Zacks Rank #2 (Buy), primarily due to a significant upward trend in its earnings estimates, a factor strongly correlated with near-term stock price movements. For the fiscal year ending December 2025, ITOS is projected to report an EPS of -$2.68, marking a 19.3% improvement from the prior year's figure. Reinforcing this positive outlook, the Zacks Consensus Estimate for the company has risen by 36.7% over the last three months. The Zacks Rank system's methodology, which focuses on such earnings estimate revisions, suggests an enhancement in the company's underlying business fundamentals. This upgrade positions ITOS within the top 20% of Zacks-covered stocks based on estimate revisions, indicating a potential for favorable stock performance in the near future as institutional investors often react to such positive shifts in earnings outlooks, further supported by an overall strongly positive sentiment (0.75 score) towards the company.

Key Decisions for Investors

• Investors should consider the Zacks Rank #2 (Buy) on ITOS as a positive signal, reflecting a significant upward revision in earnings estimates which may drive near-term stock appreciation.
• The 36.7% increase in the Zacks Consensus Estimate over the past three months indicates strengthening analyst confidence and could attract further institutional interest, warranting close monitoring of subsequent estimate revisions.
• Despite the improved earnings outlook and a 19.3% positive change in the FY2025 EPS forecast, it is crucial to acknowledge that the projected EPS remains negative at -$2.68, highlighting ongoing investment phases and inherent risks common in the biotechnology sector.